drugset
drugset / Trial / NCT06933329

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

NCT06933329 ↗

Phase 2 Active not recruiting 73 enrolled BicycleTx Limited
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).

Timeline

Start
2025-07-18
Primary completion
2028-08-31
Completion
2029-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Zelenectide pevedotin Protein / enzyme biologic — —

Indications

non-small cell lung carcinoma